-
-
-
-
-
-
-
Krystal Biotech (KRYS) Reiterated at Market Outperform After CORAL-3 FDA Submission
-
-
-
-
-
-
-
Krystal Biotech receives FDA platform technology designation for HSV-1 vector
-
-
-
-
-
-
-
Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue
-
-
-
-
-
-
-
Clear Street Starts Krystal Biotech (KRYS) at Buy
-
-
-
-
-
-
-
Krystal Biotech (KRYS) Announces European Commission Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
-
-
-
-
-
-
-
Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 31c
-
-
-
-
-
-
-
Krystal Biotech, Inc. (KRYS) Misses Q3 EPS by 8c
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

